Abstract

This paper describes the merits of both first-dollar and last-dollar coverage for pharmaceuticals. The authors highlight the fact that the insurance-model of pharmacare cannot be used to devise sound policy because drug benefits do more than simply protect individuals against unpredictable misfortune. Broader policy goals of equity and efficiency goals must be considered in pharmacare design. The argument is made that, with federal support, a universal last-dollar pharmacare system will improve financial equity by alleviating the most glaring intra- and inter-provincial disparities in coverage. Because the maintenance of targeted drug benefits for vulnerable populations and building new programs to meet disease management needs with evidence-based care would improve efficiencies in the broader healthcare sector, they should be considered as the next steps for pharmacare policy, facilitated through new injections of federal funding for the last-dollar pharmacare programs. Finally, the policy and research communities should work together to explore how the data generated by universal pharmacare programs can be used to measure and monitor the performance of products and policies in the system.